A practical reference on GLP-1 analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-23. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
colligative property Any property of a solution that depends upon the ratio of the number of solute particles to the number of solvent particles in the solution, and not on the nature of the chemical species present. Examples include osmotic pressure, freezing-point depression, and boiling-point elevation.
For voluntary service to St John Ambulance in London. Bronagh Mary Hegarty. Covid-19 Principal Pharmacist for Patient Services and Procurement, Western Health and Social Care Trust. For services to Healthcare and Pharmacy. Ian Bruce Henderson. Councillor, Kensington and Chelsea London Borough Council. For services to the community in the Royal Borough of Kensington and Chelsea. Jacqueline Ann Hendra. Social Care Assessor, Devon County Council. For services to People with Disabilities. Robert Patrick Hendry. Custodian, Prime Minister's Office. For services to the Prime Minister's Office. Daniel Herman. For services to Education and to Holocaust Awareness. Timothy John Hewer. For services to Beekeeping in Little Stoke, South Gloucestershire. Pauline Higgins. For services to the community in Liverpool, Merseyside. Donald Alexander Hill. For services to the community in County Londonderry. Felicity Ann De Grave Hills. For services to the community in Hastings, East Sussex. Andrew Richard Hinchliff. Lately Member, Conwy County Council. For services to Local Government and to the community in North Wales. Duncan Holden. Cricket Co-ordinator and Safeguarding Officer, Stoke Newington Cricket Club. For services to Sport in London. Ian Watson Holland. Lately Chair and Trustee, Enable Ayr and District SCIO. For services to People with Learning Disabilities in Ayr and Prestwick. Beverly Joan Hopkins. Special Educational Needs Co-ordinator, Palmerston Primary School, Barry. For services to Education, to People with Disabilities and to Sport. The Reverend Christopher Stewart Howson.
=== Properties === Detrital zircons usually retain similar properties as their parent igneous rocks, such as age, rough size and mineral chemistry. However, the composition of detrital zircons is not entirely controlled by the crystallization of the zircon mineral. In fact, many of them are modified by later processes in the sedimentary cycle. Depending on the degree of physical sorting, mechanical abrasion and dissolution, a detrital zircon grain may lose some of its inherent features and gain some over-printed properties like rounded shape and smaller size. On a larger scale, two or more tribes of detrital zircons from different origins may deposit within the same sedimentary basin. This gives rise to a natural complexity of associating detrital zircon populations and their sources. Zircon is a strong tool for uranium-lead age determination because of its inherent properties:
Sources: en.wikipedia.org
h = the reduced plate height count (plate height/stationary phase particle diameter) n = the reduced mobile phase linear velocity (velocity times stationary phase particle diameter/solute diffusion coefficient in the mobile phase) A, B, and C are constants related to solute flow anisotropy (eddy diffusion), molecular longitudinal diffusion, and mass transfer properties respectively. Berthod's use of the Knox equation to experimentally determine which of the proposed theories was most correct led him to the following conclusions. The flow anisotropy in micellar phase seems to be much greater than in traditional hydro-organic mobile phases of similar viscosity. This is likely due to the partial clogging of the stationary phase pores by adsorbed surfactant molecules. Raising the column temperature served to both decrease viscosity of the mobile phase and the amount of adsorbed surfactant. Both results reduce the A term and the amount of eddy diffusion, and thereby increase efficiency. The increase in the B term, as related to longitudinal diffusion, is associated with the decrease in the solute diffusion coefficient in the mobile phase, DM, due to the presence of the micelles, and an increase in the capacity factor, k¢. Again, this is related to surfactant adsorption on the stationary phase causing a dramatic decrease in the solute diffusion coefficient in the stationary phase, DS. Again an increase in temperature, now coupled with an addition of alcohol to the mobile phase, drastically decreases the amount of the absorbed surfactant.
The modification of the pKa's is a pure part of the electrostatic mechanism. The catalytic effect of the above example is mainly associated with the reduction of the pKa of the oxyanion and the increase in the pKa of the histidine, while the proton transfer from the serine to the histidine is not catalyzed significantly since it is not the rate determining barrier. Note that in the example shown, the histidine conjugate acid acts as a general acid catalyst for the subsequent loss of the amine from a tetrahedral intermediate. Evidence supporting this proposed mechanism (Figure 4 in Ref. 13) has, however, been controverted.
== Bibliography == Small, Hamish (1989). Ion chromatography. New York: Plenum Press. ISBN 978-0-306-43290-3. Tatjana Weiss; Weiss, Joachim (2005). Handbook of Ion Chromatography. Weinheim: Wiley-VCH. ISBN 978-3-527-28701-7. Gjerde, Douglas T.; Fritz, James S. (2000). Ion Chromatography. Weinheim: Wiley-VCH. ISBN 978-3-527-29914-0. Jackson, Peter; Haddad, Paul R. (1990). Ion chromatography: principles and applications. Amsterdam: Elsevier. ISBN 978-0-444-88232-5. Mercer, Donald W (1974). "Separation of tissue and serum creatine kinase isoenzymes by ion-exchange column chromatography". Clinical Chemistry. 20 (1): 36–40. doi:10.1093/clinchem/20.1.36. PMID 4809470. Morris, L. J. (1966). "Separations of lipids by silver ion chromatography". Journal of Lipid Research. 7 (6): 717–732. doi:10.1016/S0022-2275(20)38948-3. PMID 5339485. Ghosh, Raja (2002). "Protein separation using membrane chromatography: opportunities and challenges". Journal of Chromatography A. 952 (1): 13–27. doi:10.1016/s0021-9673(02)00057-2. PMID 12064524.
Sources: en.wikipedia.org
Mary Osborn (born in 1940) is a L'Oréal-UNESCO Women in Science Award-winning English cell biologist who, until she stopped running an active laboratory in 2005, was on the scientific staff at the Max Planck Institute for Biophysical Chemistry, Göttingen, Germany. Osborn established two techniques frequently used by cell biologists. She pioneered both molecular weight determination of proteins using SDS PAGE and immunofluorescence microscopy. Osborn also used the immunofluorescence microscopy method to work out the details of the eukaryotic cytoskeleton. Small differences in the intermediate filament constituents helped her distinguish differentiated cells from each other. She also found intermediate filament immunofluorescence differences between normal versus cancer cells. Mary Osborn has been a prominent spokesperson for women in science.
== Motive == The prosecution said that McTavish had been inspired by an episode of the detective series A Man Called Ironside, in which a character said that insulin was untraceable as a murder weapon and proceeded to murder a person using this method. McTavish had notably discussed with colleagues how the programme had taught her that soluble insulin would be an untraceable agent for homicide.
Short sections of chain (10 links, a swivel, and a clevis) were attached across each raft then joined to create a continuous boom of chains and rafts once afloat. Captain Thomas Machin, the artillery officer and engineer who had installed the chain at Fort Montgomery, directed installation across the river on April 30, 1778. Both ends were anchored to log cribs filled with rocks, the southern at a small cove on the west bank and the northern at Constitution Island. The West Point side was protected by the Chain Battery and the Constitution Island side by the Marine Battery. A system of pulleys, rollers, ropes, and mid-stream anchors were used to adjust the chain's tension to overcome the effects of river current and changing tide. Until 1783, the chain was removed each winter and reinstalled each spring to avoid destruction by ice. The British never attempted to run the chain, in spite of Benedict Arnold claiming in correspondence with them that "a well-loaded ship could break the chain." Polish engineer and Patriot volunteer Thaddeus Kościuszko contributed to the system of fortifications at West Point.
Owing to its location, the present territory of Colombia was a corridor of early human civilization from Mesoamerica and the Caribbean to the Andes and Amazon basin. The oldest archaeological finds are from the Pubenza and El Totumo sites in the Magdalena Valley 100 kilometers (62 mi) southwest of Bogotá. These sites date from the Paleoindian period (18,000–8000 BCE). At Puerto Hormiga and other sites, traces from the Archaic Period (~8000–2000 BCE) have been found. Vestiges indicate that there was also early occupation in the regions of El Abra and Tequendama in Cundinamarca. The oldest pottery discovered in the Americas, found in San Jacinto, dates to 5000–4000 BCE. Indigenous people inhabited the territory that is now Colombia by 12,500 BCE. Nomadic hunter-gatherer tribes at the El Abra, Tibitó and Tequendama sites near present-day Bogotá traded with one another and with other cultures from the Magdalena River Valley. A site including eight miles (13 km) of pictographs that is under study at Serranía de la Lindosa was revealed in November 2020. Their age is suggested as being 12,500 years old (c. 10,480 B.C.) by the anthropologists working on the site, because of extinct fauna depicted. It was during the earliest known human occupation of the area. Between 5000 and 1000 BCE, hunter-gatherer tribes transitioned to agrarian societies; fixed settlements were established, and pottery appeared.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.